Siglecs in immunotherapy: current clinical landscape and prospects

Area of Science:

• Immunology
• Glycobiology
• Therapeutic Development

Background:

• Siglecs (sialic acid-binding immunoglobulin-like lectins) are key regulators of immune signaling and homeostasis via glycan recognition.
• Their significant role in immune modulation presents underexplored therapeutic potential.
• Recent advances in antibody engineering and glycan biology illuminate Siglec-ligand interactions for therapeutic applications.

Purpose of the Study:

• To review preclinical and clinical progress in Siglec-targeted immunotherapies.
• To emphasize the mechanisms, safety, and efficacy of these emerging therapies.
• To propose a translational framework for accelerating Siglec-based therapy development.

Main Methods:

• Literature review of preclinical studies.
• Analysis of recent clinical trial data.
• Evaluation of Siglec-ligand interaction mechanisms.

Main Results:

• Siglec-targeted immunotherapies demonstrate promise in modulating immunosuppression for cancer and autoimmune diseases.
• Current clinical trials predominantly target Siglec-2 and Siglec-3, with a focus on hematological malignancies.
• Advances highlight the potential for Siglec-based strategies in broader immunotherapy applications.

Conclusions:

• Siglec-targeted immunotherapies represent a promising frontier in treating cancer and autoimmune disorders.
• Further research and translational efforts are needed to fully realize the therapeutic potential of Siglecs.
• A structured framework can accelerate the development and clinical translation of Siglec-based immunotherapies.